Sevelamer Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global sevelamer market is anticipated to grow at a CAGR of 5.5% during the forecast period (2022-2028). The geriatric population of the Asia-Pacific region, which suffers most from chronic kidney disease is rising, which is increasing the demand for sevelamer drugs. For instance, in 2021, According to National Kidney Foundation, 10% of the population globally is affected by chronic kidney disease (CKD), and millions die each year due to not having access to affordable treatment. After COVID-19, the online distribution channel is anticipated to propel over the forecast period, owing to the rising inclination of the population towards the internet. Thus, further driving the online penetration compared to offline pharmacies.

Sevelamer comes as a tablet and as a powder for the suspension to take by mouth. It is usually taken three times a day with meals. The sales of tablet segment are more than powder segment, the powder is for oral suspension, and it is generally used in hospitals when a patient is not able to take a tablet, also its effects fast in the body. The increase in healthcare facilities in developing countries and government policies regarding awareness of the treatment and making it less expensive for everyone will propel the sevelamer market growth. Continuous research and development activities is going around to make the sevelamer cheap and to find alternative uses of sevelamer, so it can be used in other treatments also to increase sales. There are some areas untapped where treatment is not available for chronic kidney disease as well as awareness of the medicines are also not there, so it becomes a potential market in the forecasted period to grow the market of sevelamer.

Chronic kidney disease occurs when a disease or condition impairs kidney function, causing kidney damage to worsen over several months or years. Diseases and conditions that cause chronic kidney disease are type 1 or type 2 diabetes, high blood pressure, Glomerulonephritis, Interstitial nephritis, Polycystic kidney disease, or other inherited kidney diseases. Prolonged obstruction of the urinary tract, from conditions such as enlarged prostate, kidney stones, and some cancers. Sevelamer is used to control high blood levels of phosphorus in people with chronic kidney disease who are on dialysis (medical treatment to clean the blood when the kidneys are not working properly).

Lupin Ltd. has received US drug regulator’s approval to market sevelamer hydrochloride tablets. Sevelamer hydrochloride tablets are a generic equivalent of Renagel tablets, 400 mg and 800 mg, of Genzyme Corporation. The drug is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Some major players in the market include Amneal Pharmaceuticals LLC., Aurobindo Pharmaceuticals USA, Inc., Cipla Inc., Lupin Ltd, SANOFI, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in May 2018 Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. completed their business combination to form Amneal Pharmaceuticals, Inc. As a diversified company with a robust generics business, Amneal is the 5th largest generics business in the US, with a growing, high-margin specialty franchise.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Amneal Pharmaceuticals LLC., Aurobindo Pharmaceuticals USA, Inc., Cipla Inc., Lupin Ltd, SANOFI, among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Sevelamer Market Report by Segment

By Type

• Tablet
• Oral Suspension

By Application

• Adult
• Pediatric